Free Trial

Azenta Q1 2023 Earnings Report

Azenta logo
$50.43 +0.93 (+1.88%)
(As of 12/20/2024 05:45 PM ET)

Azenta EPS Results

Actual EPS
$0.12
Consensus EPS
$0.05
Beat/Miss
Beat by +$0.07
One Year Ago EPS
$0.12

Azenta Revenue Results

Actual Revenue
$178.00 million
Expected Revenue
$181.38 million
Beat/Miss
Missed by -$3.38 million
YoY Revenue Growth
+27.10%

Azenta Announcement Details

Quarter
Q1 2023
Time
Q1 2023 Earnings Release

Conference Call Resources

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

Azenta Earnings Headlines

Azenta (NASDAQ:AZTA) Upgraded by Stephens to "Overweight" Rating
Stephens & Co. Upgrades Azenta (AZTA)
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
See More Azenta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azenta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azenta and other key companies, straight to your email.

About Azenta

Azenta (NASDAQ:AZTA) provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

View Azenta Profile

More Earnings Resources from MarketBeat

Upcoming Earnings